United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $489.42 -1.64%
Revenue Growth %: -1.2%
Financial Fact:
Income tax expense: -77.3M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -1.2%
Financial Fact:
Income tax expense: -77.3M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
- Citi expects Micron stock to rally into this event
- Interactive Strength reports record Q2 results, raises Q3 guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
